NCT03498716 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 1098
- group Id
- BG001
- value
- 1101
- group Id
- BG002
- value
- 2199
- units
- Participants
- groups
- description
- Participants were administered paclitaxel, 80 mg/m\^2, IV infusion QW for maximum of 36 weeks followed by dose-dense doxorubicin, 60 mg/m\^2 or dose-dense epirubicin, 90 mg/m\^2 IV (investigator's choice) plus cyclophosphamide, 600 mg/m\^2, IV repeated every Q2W for a maximum of 20 weeks supported with G-CSF or GM-CSF treatment.
- id
- BG000
- title
- Chemotherapy
- description
- Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\^2 or dose-dense epirubicin, 90 mg/m\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.
- id
- BG001
- title
- Atezolizumab and Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.4
- value
- 52.8
- group Id
- BG001
- spread
- 11.9
- value
- 52.3
- group Id
- BG002
- spread
- 11.6
- value
- 52.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1094
- group Id
- BG001
- value
- 1101
- group Id
- BG002
- value
- 2195
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 100
- group Id
- BG001
- value
- 75
- group Id
- BG002
- value
- 175
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 906
- group Id
- BG001
- value
- 950
- group Id
- BG002
- value
- 1856
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 168
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 57
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 401
- group Id
- BG001
- value
- 423
- group Id
- BG002
- value
- 824
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 567
- group Id
- BG001
- value
- 554
- group Id
- BG002
- value
- 1121
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 86
- group Id
- BG002
- value
- 185
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Intent-to-Treat (ITT) population included all randomized participants, whether or not the assigned study treatment was received.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 1098
- group Id
- BG001
- value
- 1101
- group Id
- BG002
- value
- 2199
- units
- Participants
- groups
- description
- Participants were administered paclitaxel, 80 mg/m\^2, IV infusion QW for maximum of 36 weeks followed by dose-dense doxorubicin, 60 mg/m\^2 or dose-dense epirubicin, 90 mg/m\^2 IV (investigator's choice) plus cyclophosphamide, 600 mg/m\^2, IV repeated every Q2W for a maximum of 20 weeks supported with G-CSF or GM-CSF treatment.
- id
- BG000
- title
- Chemotherapy
- description
- Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\^2 or dose-dense epirubicin, 90 mg/m\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.
- id
- BG001
- title
- Atezolizumab and Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.4
- value
- 52.8
- group Id
- BG001
- spread
- 11.9
- value
- 52.3
- group Id
- BG002
- spread
- 11.6
- value
- 52.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1094
- group Id
- BG001
- value
- 1101
- group Id
- BG002
- value
- 2195
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 100
- group Id
- BG001
- value
- 75
- group Id
- BG002
- value
- 175
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 906
- group Id
- BG001
- value
- 950
- group Id
- BG002
- value
- 1856
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 92
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 168
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 57
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 401
- group Id
- BG001
- value
- 423
- group Id
- BG002
- value
- 824
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 10
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 567
- group Id
- BG001
- value
- 554
- group Id
- BG002
- value
- 1121
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 86
- group Id
- BG002
- value
- 185
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Intent-to-Treat (ITT) population included all randomized participants, whether or not the assigned study treatment was received.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle